The French government is taking a proactive stance regarding the potential sale of Doliprane, a widely used medication, by Sanofi to an American investment fund, CD&R. Minister for Industry Marc Ferracci emphasized that the state could legally oppose the sale if commitments regarding industrial employment, production volumes, and research and development are not met. Government spokesperson Maud Bregeon reinforced the importance of maintaining production and jobs in France, stating that the government's demands include keeping the headquarters in France and ensuring a steady supply of Doliprane.
President Emmanuel Macron also expressed confidence in the government's ability to safeguard France's interests amid this potential change in ownership. He highlighted the necessity of producing essential medications within France and reassured that the government possesses the necessary tools to protect the country's pharmaceutical supply chain. Macron's comments reflect a broader concern about national sovereignty and the implications of foreign investment in critical industries.
- The French government's intervention in the Doliprane sale underscores the growing scrutiny over foreign investments in key sectors, particularly healthcare. The Ministry of the Economy has outlined four specific commitments that Sanofi and the potential new owners must adhere to, focusing on governance, economic footprint, supply continuity, and the relocation of paracetamol production to France. Failure to comply with these commitments could result in financial penalties, a move that signals the government's determination to maintain control over essential pharmaceutical resources.
- This situation is part of a larger trend in France, where there is increasing vigilance regarding foreign ownership in strategic industries. As the government seeks to balance economic interests with national security, the Doliprane case could set a precedent for future transactions involving critical healthcare assets.
